GlassScriptPhysician profile
Clariza Sanchez
NPI 1194076083
$1,569.04
in general payments reported to CMS, 2019-2025
31 companies · $848 in 2025
The $848 reported for 2025 was more than what 88% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $141 · 2023: $159 · 2024: $309 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $271.93 | 2024-2025 | Fintepla, Rystiggo, Nayzilam |
| Neurelis, INC. | $129.65 | 2025 | Valtoco |
| Emd Serono, INC. | $112.02 | 2021-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $93.54 | 2023-2025 | Ultomiris |
| Abbvie INC. | $85.03 | 2022-2024 | |
| Integra Lifesciences Corporation | $74.00 | 2021-2024 | Codman Certas, Codman Hakim, Cusa Clarity |
| Takeda Pharmaceuticals U.S.A., INC. | $60.60 | 2024 | Hyqvia |
| Merz Pharmaceuticals, LLC | $59.19 | 2023-2025 | Xeomin, Ampyra, Inbrija |
| Astrazeneca Pharmaceuticals LP | $54.16 | 2025 | Wainua |
| Biogen, INC. | $44.72 | 2025 | Skyclarys |
| Janssen Scientific Affairs, LLC | $42.34 | 2024 | Xarelto |
| Acorda Therapeutics, INC | $42.00 | 2024 | Inbrija, Ampyra |
| Jazz Pharmaceuticals INC. | $41.61 | 2022 | |
| Lilly USA, LLC | $41.29 | 2023-2025 | Kisunla, Amyvid |
| Teva Pharmaceuticals USA, INC. | $38.37 | 2025 | Austedo Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $35.45 | 2022-2023 | Ingrezza, Ongentys |
| Livanova USA, INC. | $31.78 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $31.60 | 2025 | |
| Stryker Corporation | $30.47 | 2021 | |
| Eisai INC. | $28.35 | 2025 | |
| Tersera Therapeutics LLC | $25.50 | 2025 | Zoladex |
| Sk Life Science, INC. | $25.23 | 2025 | |
| Omniscient Neurotechnology America LTD | $25.05 | 2023 | Quicktome |
| Argenx US, INC. | $23.46 | 2022 | |
| Novo Nordisk INC | $21.18 | 2024 | |
| Lundbeck LLC | $20.13 | 2024 | Vyepti |
| Cycle Pharmaceuticals INC | $17.67 | 2025 | Bafiertam, Tascenso Odt |
| Chiesi USA, INC. | $16.46 | 2025 | Cleviprex |
| Acadia Pharmaceuticals INC | $16.37 | 2025 | Nuplazid |
| Bioventus LLC | $16.31 | 2025 | Nexus-10 Mkii |
| Genzyme Corporation | $13.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clariza Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.